We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Ed Hurwitz joined MPM in 2017. Prior to MPM, Hurwitz was Founder and Managing Director of Precision BioVentures LLC where he focused on founding and seeding start-up biotechnology companies, including Viewpoint Therapeutics. Prior to that, Ed was a Director of two funds at Alta Partners — Alta BioPharma Management III and Alta Partners Management VIII. While at Alta, Hurwitz led twelve successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics, Inc., and Taligen Therapeutics (acquired by Alexion).
Over the course of his career, Hurwitz has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotech research analyst for both Robertson Stephens & Company and Smith Barney Shearson. Prior to that he practiced law at Cooley Godward LLP. Hurwitz earned his JD and MBA degrees from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, and his BA in Molecular Biology from Cornell University.
This speaker's sessions: